News

Pasadena – September 16, 2026 -- Sophia Space has entered a $300 million financing framework with aerospace leasing specialist SLI to fund a 10-satellite edge computing constellation, applying asset-leasing models long used in aviation and energy to orbital infrastructure for the first time.

SLI will purchase and lease 10 satellites under a fixed-payment structure

Under the non-binding letter of support, SLI will buy the satellites from Sophia and lease them to end-users on fixed monthly or quarterly payments, aligning the financing timeline with Sophia's build and deployment schedule. The arrangement supports purchase and deployment of 10 Sophia TILE spacecraft through a long-term operating lease spanning the satellites' expected useful lives, with mission launches planned as early as 2028.

Suzhou – – September 16, 2026 -- Accro Bioscience said AC-101 tablets have been included in the National Medical Products Administration's Center for Drug Evaluation (CDE) "Caring Plan-Extension" pilot program, targeting Blau syndrome as the proposed indication, with the public notice period closing September 11, 2026.

NMPA pilot program aims to accelerate rare disease drug development in China

The Caring Plan-Extension pilot, run by China's CDE, is designed to encourage innovative drug development for rare diseases. Accro Bioscience confirmed the inclusion took effect September 14, 2026, China Standard Time (UTC+8).

FDA granted AC-101 Rare Pediatric Disease designation three months earlier

The U.S. Food and Drug Administration awarded AC-101 Rare Pediatric Disease (RPD) designation for Blau syndrome in June 2026, ahead of the Chinese regulatory step.

Morristown, N.J. – September 16, 2026 -- Whitehawk Therapeutics (Nasdaq: WHWK) presented real-world data at the IASLC 2026 World Conference on Lung Cancer in Seoul showing that PTK7 expression remains stable in pretreated, EGFR wild-type non-small cell lung cancer (NSCLC), reinforcing the target biology behind its Phase 1 antibody-drug conjugate (ADC) HWK-007.

Seoul – September 16, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Combination therapy nearly doubles historical survival benchmarks

The result marks the longest reported median overall survival for this patient population, which has historically faced a five-year survival rate of just 8 percent and a median overall survival ranging from 16 to 24 months. EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations and have proven difficult to treat with existing targeted therapies.

Shanghai – September 16, 2026 -- Shanghai Electric has secured its first overseas heavy-duty gas turbine contract, landing the Unit 3 award for the 500 MW Sarawak Samalaju Combined Cycle Gas Turbine Project in Malaysia.

Shanghai Electric will deliver full EPC turnkey scope plus a 25-year service agreement

The contract covers a complete engineering, procurement and construction turnkey solution for the gas-fired plant, paired with a 25-year long-term service agreement (LTSA) spanning all major equipment. Gas turbines, steam turbines, generators, heat recovery steam generators and air-cooled systems will all be manufactured in-house by Shanghai Electric, which will also act as the sole provider for decades of maintenance and service.

Toronto – September 16, 2026 -- Franco-Nevada Corporation has agreed to a A$200 million (approximately $144 million) follow-on financing package with Minerals 260 Limited to advance the Bullabulling Gold Project in Western Australia, lifting its total backing of the project to an aggregate A$420 million (approximately $300 million).

The package comprises a A$170 million (approximately $122 million) gross royalty acquisition and a A$30 million (approximately $22 million) equity subscription as lead order in a future Minerals 260 capital raise.

Melbourne – September 16, 2026 -- IonOpticks has released Aurora Series 5, a nano-LC column platform that sustained over 10,000 unique protein identifications across more than 1,000 injections in extended laboratory testing, without a rise in backpressure beyond 1,400 runs.

Extended testing confirms durability across 1,400-plus injections on an 8-minute, 120-samples-per-day method

Testing was conducted on a Thermo Scientific Vanquish Neo UHPLC coupled to an Orbitrap Astral Zoom mass spectrometer. IonOpticks says the results allow laboratories to run nanoflow-level depth and sensitivity as a routine, high-throughput workflow rather than reserving it for select experiments.

The Woodlands, Texas – September 16, 2026 -- CB&I and AG&P Industrial have completed and commissioned two 60,000m3 full containment LNG storage tanks at the LNGPH Ilijan LNG Facility in the Philippines, marking the world's first in-service full containment all-steel LNG tanks.

Tank 1 achieves world-first status as all-steel full containment LNG storage

The commissioning of Tank 1 marked the industry's first in-service full containment LNG tank built entirely of steel. Tank 2 has since completed performance testing and is fully operational, giving the Ilijan facility two functioning units of the technology.

Fort Worth – September 16, 2026 -- BODYBAR Pilates completed the largest reformer Pilates class on record in the United States, gathering 100 participants on 100 reformers in Frisco, Texas, and raising $10,000 for the Foundation for Women's Cancer.

Franchise stages record-setting class tied to two milestones

The 50-minute session, held Sunday, September 13, coincided with the 100th anniversary of Pilates and BODYBAR's own 100th studio opening. The event took place during BODYBAR's annual franchise conference at the Omni Frisco Hotel at The Star and included franchise owners, instructors and media from across the brand's network.

Kamille McCollum, BODYBAR's Chief Brand Officer, President and Co-Founder, led the class alongside a team of certified instructors. She said the event exceeded expectations and reflected the growth of both the Pilates discipline and the franchise's community.

Seoul – September 16, 2026 -- Risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, reduced the risk of death by 54% compared with topotecan in patients with relapsed small-cell lung cancer, according to Phase III ARTEMIS-008 trial results presented at the IASLC 2026 World Conference on Lung Cancer.

Ris-Rez extends median overall survival to 18.5 months versus 10.3 months for topotecan

The multicenter, open-label trial (NCT06498479) randomized 461 patients in China 1:1 to receive Ris-Rez at 8.0 mg/kg every three weeks or topotecan at 1.2 mg/m2 on days 1 through 5 every three weeks. More than 80% of enrolled patients had previously received PD-(L)1 inhibitors. At the June 6, 2026 data cutoff, after a median follow-up of 12.2 months, the hazard ratio for death favored Ris-Rez at 0.46 (95% CI, 0.35–0.62; P0.0001), with the survival benefit consistent across relevant subgroups.